- Home
- AYTU vs DRK Comparison
AYTU vs DRK Comparison
Compare AYTU & DRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AYTU | DRK |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 26.9M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AYTU | DRK |
|---|---|---|
| Price | $2.01 | $2.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | 40.1K | ★ 182.8K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,632,080.00 | $11,181,000.00 |
| Revenue This Year | $17.96 | $14.11 |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.80 | $1.98 |
| 52 Week High | $3.07 | $3.27 |
Technical Indicators
Market Signals| Indicator | AYTU | DRK |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 21.80 |
| Support Level | $1.94 | N/A |
| Resistance Level | $2.34 | $2.40 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 48.55 | 6.19 |
Price Performance
Historical ComparisonAbout AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.